Position: Professor of Medicine
Location: Cleveland, US

Mina K. Chung, MD, is a clinical cardiac electrophysiologist and translational scientist at the Cleveland Clinic. Her goal is to bring basic advances in arrhythmia research back to the bedside as soon as possible.

She worked on seminal studies in upstream therapies, genetics and genomics in AF. She and her multidisciplinary group have had NIH and AHA funding to study the genetics and functional genomics of AF, including inducible pluripotent stem cell technologies allowing creation of patient-specific cardiomyocyte models for exploring genetic mechanisms of AF and inherited cardiac diseases, exploring artificial intelligence and big data analyses using machine learning methodologies, a clinical trial testing genomically based drug and lifestyle modifications for AF, and NIH program project studies of AF from genes to treatment. Her group’s functional genomics infrastructure has expanded to other cardiovascular diseases, including aortic, pericardial, heart failure, and other arrhythmia conditions.

She is also actively promoting new approaches to accelerate acute detection and deployment for sudden cardiac arrest. Dr. Chung was chair of the 2020 AHA Scientific Statement on lifestyle and risk factor modification for reduction of AF and the 2023 HRS Guideline on cardiac physiologic pacing, and vice chair of the 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial AF. She holds leadership roles in several professional societies, including 1st VP of the Heart Rhythm Society. She has been named in Best Doctors in America since 2001 and has received the Cleveland Clinic Research Mentor, Clinical Research, and Excellence in Research awards.